| Aguia Resources Limited (AGR) ORDINARY FULLY PAID |
Materials |
$40 |
Investor Presentation
|
12 Jun 2025 8:39AM |
$0.040 |
$0.020 |
fallen by
50%
|
|
AGR - Price-sensitive ASX Announcement
Full Release
Key Points
- Aguia Resources Limited (AGR) is focused on developing phosphate projects for agribusiness in southern Brazil.
- The Três Estradas Phosphate Project is AGR’s flagship asset, located in a region with significant agricultural activity.
- Project development has advanced with updated feasibility studies, expanded resource estimates, and improved project economics.
- Key permits and environmental licenses have been obtained, enabling progression toward construction.
- Brazil's heavy reliance on imported phosphate underpins strong domestic demand for AGR’s planned production.
- Phosphate is a critical agricultural input, positioning AGR to supply Brazil’s growing fertilizer market.
- AGR’s strategy includes phased project development, with initial smaller-scale operations expanding over time.
- The company is engaged in securing project financing and strategic partnerships to support development.
- Experienced management and technical teams are guiding project execution.
- Environmental, social, and governance (ESG) considerations are central to AGR’s development philosophy.
- Updates on project milestones, permitting, construction plans, and estimated commissioning timelines are provided.
- The company aims to deliver strong returns to shareholders through disciplined development and market positioning.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$6,540 |
Update - Notification of buy-back - WHC
|
12 Jun 2025 8:38AM |
$5.740 |
$7.930 |
risen by
38.15%
|
|
| ASX Limited (ASX) ORDINARY FULLY PAID |
Financials |
$11,650 |
Investor Forum 2025 and Financial Guidance
|
12 Jun 2025 8:36AM |
$71.910 |
$59.620 |
fallen by
17.09%
|
|
ASX - Price-sensitive ASX Announcement
Full Release
Key Points
- ASX Limited conducted its 2024 Investor Forum outlining strategy, performance, and outlook.
- Emphasis on technology transformation, including CHESS replacement progress and learnings.
- Focus on operational resilience, regulatory compliance, and stakeholder trust.
- Reaffirmation of FY24 financial guidance, with details on revenue and expense expectations.
- Provided FY25 guidance, including operating expense and capital expenditure forecasts.
- Updates on regulatory environment, market trends, and competition landscape.
- Discussion on capital management strategy, dividend policy, and shareholder returns.
- Ongoing commitment to growth, efficiency, and stakeholder engagement.
- Enhanced transparency around major projects, risks, and investment priorities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orora Limited (ORA) ORDINARY FULLY PAID |
Materials |
$1,746 |
Update - Notification of buy-back - ORA
|
12 Jun 2025 8:34AM |
$1.855 |
$1.425 |
fallen by
23.18%
|
|
| Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID |
Health Care |
$93 |
Corporate Presentation
|
12 Jun 2025 8:33AM |
$0.360 |
$0.680 |
risen by
88.89%
|
|
COV - Price-sensitive ASX Announcement
Full Release
Key Points
- Cleo Diagnostics Ltd is focused on commercializing a blood-based diagnostic test for early detection and risk stratification of ovarian cancer.
- Ovarian cancer has a high mortality rate largely due to late-stage diagnosis and inadequate current diagnostic methods.
- Cleo’s test demonstrates improved sensitivity and specificity over existing diagnostic tools, especially for early-stage ovarian cancer.
- There is a significant unmet clinical need and a multi-billion-dollar global market opportunity for improved ovarian cancer diagnostics.
- The company’s proprietary biomarker panel is scientifically validated with promising clinical trial results.
- Cleo’s regulatory strategy targets CE Mark (Europe), TGA (Australia), and FDA (USA) approvals, with a clear roadmap to market entry.
- The presentation details a go-to-market plan including early adoption by specialist clinicians, payer strategy, and potential global partnerships.
- Competitive advantages include first-mover potential, validated technology, scalable platform, and a strong leadership and advisory team.
- Ongoing and planned clinical studies are designed to further validate test performance and support regulatory submissions.
- Cleo Diagnostics positions itself as a strong investment opportunity with the potential to transform the clinical management of ovarian cancer globally.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thorney Opportunities Ltd (TOP) ORDINARY FULLY PAID |
Financials |
$85 |
Update - Notification of buy-back - TOP
|
12 Jun 2025 8:33AM |
$0.635 |
$0.500 |
fallen by
21.26%
|
|
| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$150 |
FY25 Revenue Guidance Upgrade
|
12 Jun 2025 8:32AM |
$0.026 |
$0.066 |
risen by
153.85%
|
|
BXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Bioxyne Limited (ASX: BXN) upgrades FY25 revenue guidance to between $150 million and $180 million.
- The upgrade is attributed to robust health and wellness business growth in Asia.
- Expansion of distribution channels and increased product demand are key drivers.
- The company is focusing on product innovation and strengthening its supply chain.
- Bioxyne is pursuing new partnership opportunities to support continued growth.
- Initiatives are aimed at reinforcing Bioxyne’s position in the global health and wellness sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brazilian Rare Earths Limited (BRE) ORDINARY FULLY PAID |
Materials |
$1,351 |
Monte Alto Metallurgical Results Deliver High-Purity MREC
|
12 Jun 2025 8:32AM |
$2.140 |
$4.840 |
risen by
126.17%
|
|
BRE - Price-sensitive ASX Announcement
Full Release
Key Points
- Brazilian Rare Earths Limited (BRE) reported successful metallurgical results from Monte Alto project.
- High-purity mixed rare earth carbonate (MREC) was produced with a 99% recovery rate.
- The extraction process used is sulfate-free and environmentally friendly.
- Produced MREC meets or exceeds global purity standards for rare earth separation and the magnet industry.
- Monte Alto demonstrated potential as a major, sustainable rare earths supplier.
- Future plans include further bulk pilot-scale testing and a Pre-Feasibility Study (PFS).
- Project aims to supply high-purity, low-cost magnet rare earths to global markets, providing an alternative to Chinese supply.
- Monte Alto's ionic clay mineralisation is considered significant for rare earth production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$66 |
Update - Notification of buy-back - M7T
|
12 Jun 2025 8:31AM |
$0.320 |
$0.280 |
fallen by
12.50%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$143 |
Notice of Change of Interests of Substantial Holder - M Azzi
|
12 Jun 2025 8:31AM |
$0.175 |
$0.585 |
risen by
234.29%
|
|
| Cochlear Limited (COH) ORDINARY FULLY PAID |
Health Care |
$6,367 |
Cochlear launches new cochlear implant system
|
12 Jun 2025 8:30AM |
$270.460 |
$97.350 |
fallen by
64.01%
|
|
| Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID |
Health Care |
$71 |
Notice Under Section 708A
|
12 Jun 2025 8:30AM |
$0.026 |
$0.020 |
fallen by
23.08%
|
|
| Platinum Capital Limited (PMC) ORDINARY FULLY PAID |
Financials |
- |
L1 Capital Voting Intentions re Scheme
|
12 Jun 2025 8:29AM |
$1.340 |
$1.765 |
risen by
31.72%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,618 |
Net Tangible Asset Backing
|
12 Jun 2025 8:29AM |
$2.800 |
$4.130 |
risen by
47.50%
|
|
| ACDC Metals Ltd (ADC) ORDINARY FULLY PAID |
Materials |
$4 |
Outstanding Economic Potential with Goschen Central Study
|
12 Jun 2025 8:27AM |
$0.037 |
$0.059 |
risen by
59.46%
|
|
ADC - Price-sensitive ASX Announcement
Full Release
Key Points
- ACDC Metals Ltd released results of an independent Goschen Central Study highlighting excellent economic potential.
- The project shows a pre-tax NPV of $417 million and an IRR of 50%, with a 1.6-year payback period.
- Project economics are underpinned by mineral sands and rare earths production, with further optimization opportunities identified.
- Key opportunities include increasing ore throughput, enhancing mineral recoveries, and reducing operating and capital expenses.
- The Goschen Central Project holds a substantial resource base and aligns with global demand for critical minerals.
- The processing flowsheet is designed to maximize recovery of valuable heavy minerals and rare earths.
- Project development will focus on progressing toward a definitive feasibility study, stakeholder engagement, and funding strategies.
- The company emphasizes responsible environmental practices and strong engagement with government and local communities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WIA Gold Limited (WIA) ORDINARY FULLY PAID |
Materials |
$761 |
Drilling continues to return high-grade mineralisation
|
12 Jun 2025 8:25AM |
$0.245 |
$0.515 |
risen by
110.20%
|
|
WIA - Price-sensitive ASX Announcement
Full Release
Key Points
- WIA Gold Limited continues drilling at Kokoseb, Damaran Gold Project, Namibia.
- Recent drilling returned high-grade gold mineralisation from both diamond and reverse circulation programs.
- Significant gold intersections confirm continuity of mineralisation along strike and at depth.
- Mineralisation remains open in multiple directions, offering potential for further expansion.
- Results support WIA’s confidence in Kokoseb and the broader Damaran Gold Project.
- The drilling program aims to further define the resource and expand the mineralised footprint.
- WIA is well-funded to continue its exploration and drilling activities in Namibia.
- Company highlights ongoing commitment to systematic exploration and resource development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Small Cap Opportunities Company Limited (NSC) ORDINARY FULLY PAID |
Financials |
$48 |
NTA & Portfolio Update - May 2025
|
12 Jun 2025 8:24AM |
$0.290 |
$0.365 |
risen by
25.86%
|
|
| Venus Metals Corporation Limited (VMC) ORDINARY FULLY PAID |
Materials |
$46 |
Encouraging Gold Results Bellchambers Gold Deposit
|
12 Jun 2025 8:24AM |
$0.115 |
$0.235 |
risen by
104.35%
|
|
VMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Venus Metals Corporation Limited announced positive gold assay results from RC drilling at the Bellchambers Gold Deposit.
- The Bellchambers Gold Deposit is part of the Youanmi Gold Project in Western Australia.
- Recent drilling confirmed significant gold intersections and the continuity of mineralization.
- Results support the potential to expand the known gold resource at Bellchambers.
- The company plans to conduct further drilling and resource assessment to advance the project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flight Centre Travel Group Limited (FLT) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,185 |
Update - Notification of buy-back - FLT
|
12 Jun 2025 8:24AM |
$13.300 |
$10.600 |
fallen by
20.30%
|
|
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$26 |
Notification of buy-back - NACGA
|
12 Jun 2025 8:24AM |
$0.475 |
$0.565 |
risen by
18.95%
|
|
| NAOS Small Cap Opportunities Company Limited (NSC) ORDINARY FULLY PAID |
Financials |
$48 |
Update - Notification of buy-back - NSC
|
12 Jun 2025 8:24AM |
$0.290 |
$0.365 |
risen by
25.86%
|
|
| Argo Investments Limited (ARG) ORDINARY FULLY PAID |
Financials |
$6,556 |
Update - Notification of buy-back - ARG
|
12 Jun 2025 8:24AM |
$9.130 |
$8.640 |
fallen by
5.37%
|
|
| Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID |
Health Care |
$71 |
Application for quotation of securities - RAD
|
12 Jun 2025 8:24AM |
$0.026 |
$0.020 |
fallen by
23.08%
|
|
| Karoon Energy Ltd (KAR) ORDINARY FULLY PAID |
Energy |
$1,593 |
Update - Notification of buy-back - KAR
|
12 Jun 2025 8:24AM |
$1.755 |
$2.240 |
risen by
27.64%
|
|
| Solvar Limited (SVR) ORDINARY FULLY PAID |
Financials |
$297 |
Update - Notification of buy-back - SVR
|
12 Jun 2025 8:24AM |
$1.625 |
$1.570 |
fallen by
3.38%
|
|
Call 1300 880 160
Start a chat
Schedule a call
